

## 17<sup>th</sup> JPIAMR transnational call for research projects within the ERA-NET JPIAMR-ACTION

# “Interventions Moving forward to Promote ACTION to counteract the emergence and spread of bacterial and fungal resistance and to improve treatments”

Short title: IMPACT

*Call text v.2024-01-10*

## Contents

<b>1. Introduction</b>	2
<b>2. Aim of the call</b>	3
2.1 Topics of the call	3
2.2 One Health settings	4
2.3 Type of studies/experimental approaches	4
<b>3. Application</b>	4
3.1 Eligibility	4
3.2. Widening participation	6
3.3 Submission of joint transnational proposal	7
3.4 Financial modalities and funding prerequisites	8
3.5 Contact persons	9
<b>4. Evaluation</b>	9
4.1 Scoring system	10
4.2 Proposal evaluation criteria	10
4.3 Ethics and legal requirements	11
4.4 Social and gender equity, cultural sensitivity, and economic viability	12
<b>5. Decision of project to be funded</b>	12
<b>6. Reporting requirements and other obligations of JPIAMR grantees</b>	12
<b>7. Intellectual Property</b>	13
<b>8. Project partner Consortium Agreement</b>	13
<b>9. Open access and FAIR data</b>	14
<b>10. General Data Protection Regulation (GDPR)</b>	15
<b>11. Privacy</b>	16
<b>12. Acknowledgements</b>	16
<b>Annex A: National contact persons for each party providing funding</b>	17
<b>Annex B : National Rules and Requirements</b>	19

**Important note to applicants:** Applications to JPIAMR joint transnational calls can require the submission of additional information on national funding platforms. All applicants must have fulfilled both joint and national requirements for an application to be eligible. Please read the national requirements in Annex B to ensure your application is eligible.

## 1. Introduction

Antimicrobial resistance (AMR) affects humans, animals and plants without geographic borders or species barriers. Progress on AMR is necessary to achieve the United Nations (UN) Sustainable Development Goals (SDGs), with AMR being deeply rooted into attainment of SDGs promoting no poverty, good health and wellbeing, zero hunger, reduced inequality, decent work and international growth. The European One Health (OH) Action Plan against AMR<sup>1</sup> encourages the EU and its Member States to deliver innovative, effective and sustainable responses to AMR, especially to reduce the emergence and spread of AMR inside and outside the EU. Addressing the rising threat of antimicrobial resistance (AMR) requires a holistic and multi-sectoral approach – referred to as One Health.

This call, developed under the ERA-Net JPIAMR-ACTION, is the 17<sup>th</sup> JPIAMR transnational call for research projects. Declining effectiveness of existing antimicrobials together with the low and insufficient number of promising new antimicrobials in the pipeline stresses the need for developing new treatments, measures and strategies, especially against fungi. Fungal infections are an under-recognized component of antimicrobial resistance, which is an emerging crisis worldwide. Resistance of pathogenic fungi to all licenced systemic antifungals has been documented, therefore Global efforts are required to support and direct the research and development of new therapies and interventions to treat fungal infections.

Overuse and misuse of antimicrobials and their accumulation in the environment with potential co-selection factors may favour AMR emergence and spread and accelerate the declining effectiveness of existing treatments.

Research is needed to improve, compare and evaluate the efficiency, cost effectiveness and uptake of existing interventions (including treatments and treatment prescription) aiming to control AMR emergence/ spread or to reduce mortality caused by AMR in various geographic, cultural and socio-economic settings using One Health implementation strategies.

---

<sup>1</sup> [https://ec.europa.eu/health/sites/health/files/antimicrobial\\_resistance/docs/amr\\_2017\\_action-plan.pdf](https://ec.europa.eu/health/sites/health/files/antimicrobial_resistance/docs/amr_2017_action-plan.pdf)

## 2. Aim of the call

To take action against the growing global threat of increased spread of antimicrobial (antibacterial and antifungal) resistance by funding international collaborative research projects aiming to improve, compare and evaluate the effectiveness, cost effectiveness, and uptake of existing interventions against bacterial or fungal infections and/or to design new interventions against fungal infections.

### 2.1 Topics of the call

Proposals should address **one** of the **two** topics of the call:

#### Topic 1:

Design novel or improved interventions to prevent, mitigate and /or treat fungal infections, which are resistant to treatments and/or are at risk of developing resistance

#### Topic 2:

Improve and/or, compare and/or evaluate strategies, technologies, treatments, methods, protocols or data collection based on existing interventions, aiming to prevent or reduce the emergence or spread of antibacterial or antifungal resistance or to treat/cure infections caused by resistant bacteria/fungi and recommend new policies.

**Within this topic, projects should address one or more of the following subtopics:**

- a) Improve and/or compare and/ or evaluate the effectiveness of existing interventions (e.g. cost effectiveness, clinical utility, socio-economic adaptability, reducing AMR emergence, spread, transmission, treatment etc.)
- b) Identify the barriers to uptake, including factors leading to the success or failure of previously run pilot interventions, and when applicable design solutions to overcome them.

**The novel interventions for Topic 1** may include, but are not limited to: prevention strategies, treatments based on new or existing compounds or technologies, improved or novel diagnostics or surveillance

**The prevention and/or mitigation interventions for Topic 2** may include, but are not limited to:

- Treatment (e.g. wastewater, medical, technological etc.),
- protocols
- Social, societal and behavioural intervention (e.g. public awareness campaigns, provider audit and feedback, reimbursement penalties, prescription requirements, infection prevention and control programmes),
- Stewardship efforts (e.g. antimicrobial or vaccination guidelines).

These interventions may use technological, digital, or AI based approaches.

In the framework of this call, proposals may focus within **any** individual One Health setting and are encouraged to include more than one OH setting when possible.

**For all topics:** Reuse and/or improvement of the quality and sustainability of existing data is encouraged.

For any project applying for funding to support a clinical study, please check the National Rules and Requirements (Annex B) to see if clinical studies are eligible for funding by the relevant national funding partner organizations (FPOs).

Companies are welcome to apply to this call either by requesting funding or by using other internal or external funding. **The eligibility of companies for funding from this call is determined by the relevant national FPO.** Please check the National Rules and Requirements (Annex B) to see the eligibility for funding.

The following sub-topics are **out of the scope** of the call:

- Antivirals and antiparasitics
- Proposals **solely** aiming to treat plant or animal infections without link to human health
- Proposals **solely** aiming to extend existing or implement new surveillance systems

## 2.2 One Health settings

*The call covers the following One Health settings:*

- Human Health;
- Animal Health (including wildlife, livestock, aquatic organisms, and companion animals);
- Plants (including trees and crops);
- Environment (including natural and built environment).

**The eligibility of the considered One Health setting may depend on your funding organisation.** Please check the National Rules and Requirements (Annex B) to see if the One Health setting of interest is eligible for funding.

## 2.3 Type of studies/experimental approaches

In the framework of this call all types of studies or experimental approaches are admissible, however, **the eligibility of the proposed experimental approach may depend on your national funding organisation.** Please check the National Rules and Requirements (Annex B) to see if the type of study/experimental approach of your choice is eligible for funding.

Participation of the end-users of expected project outcomes, such as parties implementing antimicrobial stewardship activities, is encouraged.

# 3. Application

## 3.1 Eligibility

Applicants must adhere to the specific regulations of their national FPO. The eligibility of the consortium will be approved by the FPOs at both pre and full proposals stages. Therefore, each project partner is strongly advised to carefully check the national eligibility rules defined by their own funding organisation, as specified in the National and Regional Requirements (see Annex B). A checklist for composing an eligible consortium is included below as Figure 1.

Eligibility rules for the consortia are:

- The consortium must include a minimum of three (3) eligible project partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries<sup>2</sup>).
- The consortium can include a maximum of six (6) project partners (including non-funded project partners, Figure 1). The maximum number of project partners can be increased to seven (7) if the consortium includes:
  - at least one project partner from an under-represented country or
  - at least one project partner where the Principal Investigator (PI) meets the definition of an Early Career Researcher or
  - a company.
- Maximum of 2 partners from the same country per proposal


For the purposes of the IMPACT call:

- **The under-represented countries** are Hungary, Lithuania, Latvia, Moldova and Poland.
  - **The Principal Investigator** is the applicant researcher scientifically responsible for the implementation of tasks by a national research team, and indicated as such in Section A of the proposal.
  - **An Early Career Researcher (ECR) for the purpose of this call** is a PhD holder, up to 8 years after the year of PhD award, holding a position at a recognized institution. The 8-year period may be extended to allow for career breaks including: parental leave, positions of trust in trade union organizations and student organizations, mandatory military or civil service, illness (own illness or care for first degree family members, medical internships or medical fellowship (applies to clinically active professionals). The last two categories may involve periods of up to 24 months each.
- Additional National Rules and Regulations (Annex B) of Funding Partner Organisations (FPOs) also apply.
  - Project partners not eligible for funding (e.g. from countries not participating in the call or not fundable according to national/regional regulations of the FPOs) may be involved in projects if they bring their own funding. The budget of non-funded project partners must be included in the proposal and shall not exceed 30% of the requested total transnational project budget.
  - A project partner not eligible to be funded cannot be the coordinator of a proposal. However, like the funded project partners, they must accept all JPIAMR rules and guidelines.
  - At both the pre- and full proposal stage, all project partners, including non-funded project partners, must submit a signed letter of intent along with their pre-/full proposal. In the absence of these letters, the proposal will be declared ineligible.
  - Composition of the consortium should not be modified between the pre- and the full proposal except for the inclusion of a new project partner as described in the paragraph 2.2 (widening), in case of force majeure/unforeseen event (e.g. change of professional affiliation, lab relocation, prolonged absence of the PI), or upon recommendation of the Peer Review Panel or request of the FPOs. In any case, changes in the composition of the consortium must be approved by the FPOs ahead of the submission of the full proposal. Consortium eligibility checklist is presented in Figure 1 on page 6.

---

<sup>2</sup> [https://ec.europa.eu/research/participants/data/ref/h2020/grants\\_manual/hi/3cpart/h2020-hi-list-ac\\_en.pdf](https://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/3cpart/h2020-hi-list-ac_en.pdf) Note: UK is an EU country for the purpose of this call.

**Figure 1.** Consortium eligibility checklist



### 3.2. Widening participation

To promote inclusiveness, ensure global participation, relevance and impact of the submitted projects in and outside Europe, as well as to maximise the use of committed resources, the Joint Call will employ the following widening measures:

- **At the pre-proposal stage** – increasing the maximum eligible size of consortia depending on their composition, as described in section 2.1.
- **At the full proposal stage** – increasing the initially declared size of consortium by adding one non-funded project partner or one project partner supported by the under-subscribed Funding Partner Organisation FPO (an FPO that is at risk of not using the total funds it committed to the call). Consortia which are invited to the second stage of the

call and which have not previously declared the maximum of seven (7) members will be able to increase their initial size by adding one new project partner eligible for funding by an under-subscribed organisation from the list **or** one new partner not requesting funding. Project coordinators will be notified of this option in their invitation letter to submit a full proposal. The list of eligible under-subscribed organisations will be included in the full proposal template.

The Joint Call Secretariat and the under-subscribed FPOs will promote the use of the Partner Search Tool (PST) – available on the JPIAMR site [www.jpiaamr.eu/calls/amr-interventions-call-2024/](http://www.jpiaamr.eu/calls/amr-interventions-call-2024/) for widening, but project coordinators could invite new project partners who are not registered in the tool. In any case, new project partners can only join consortia after their respective under-subscribed organisation confirms that they are indeed eligible according to their respective national rules and regulations. The under-subscribed organisations will inform the Joint Call Secretariat of all new project partners cleared to join at the full proposal stage.

### 3.3 Submission of joint transnational proposal

Submissions of proposals will take place in two steps: a pre-proposal and a full proposal phase. In both cases, one joint proposal document (in English, and using the provided template) shall be prepared by the project participants of a joint transnational proposal. The pre-proposal must be submitted by the project coordinator before March 14, 2024, 14h CET using the electronic submission platform link: [https://ptoutline.eu/app/jpiaamr2024\\_impact](https://ptoutline.eu/app/jpiaamr2024_impact)

In addition, some FPOs may require the submission of other documents at the national level - either at the first and/or second step. Details can be found in Annex B.

The two-step application process (pre-proposal, full proposal) will have the following targeted timetable:

November 20, 2023	Pre-announcement of the Call on European Antibiotic Awareness week 2023
January 10, 2024	Publication of the Call
January 24, 2024	Interactive webinar presentation of the Call and partner search tool.
March 14, 2024	Submission deadline for pre-proposals
May 30, 2024	Full proposal invitations sent to project coordinators
July 9, 2024	Submission deadline for full proposals
September, 2024	Final funding decision taken by the Funding Partner Organisations
October 2024	Ethical Evaluation of the selected proposals
November 2024	Final funding recommendation announced to applicants
Mid-November 2024	Publication of results: European Antibiotic Awareness Day 2024
End of 2024/early 2025	Start of funding

### 3.4 Financial modalities and funding prerequisites

Funding is initially granted for a maximum of three years in accordance with national regulations and applicable legal provisions. Applicants must comply with their own specific national regulations and scientific remits as detailed in the National and Regional Requirements or specific regulations of their corresponding funding partner organisation (see Annex B).

The financial indicative commitments made by the Funding partner Organisations are listed in the table below. Each country will fund its own approved project partners.

#### ***Initial funding committed by each Funding Partner Organisation***

Please note the different currencies. The exchange rates for funders outside the Euro-zone are listed in the National Requirements (Annex B).

<i>Country</i>	<i>Funding Partner Organisation</i>	<i>Acronym</i>	<i>Contribution</i>
Australia	National Health and Medical Research Council	NHMRC	3 M AUD
Belgium	Fonds de la Recherche Scientifique	FNRS	200,000 EUR
Canada	Canadian Institutes of Health Research	CIHR	600,000 CAD
France	Agence Nationale de la Recherche	ANR	2 M EUR
Germany	Federal Ministry of Education and Research / Deutsches Zentrum für Luft- und Raumfahrt	BMBF / DLR	2 M EUR
Hungary	National Research, Development and Innovation Fund	NKFIH	300,000 EUR
Ireland	Health Research Board	HRB	430,000 EUR
Israel	Chief Scientist Office, Ministry of Health	CSO-MOH	360,000 EUR
Italy	Fondazione Regionale per la Ricerca Biomedica	FRRB	1.5M EUR
Italy	Ministry of Health	It-MOH	800,000 EUR
Latvia	Latvia Council of Science	LCS	600,000 EUR
Lithuania	Research Council of Lithuania (Lietuvos mokslo taryba)	LMT	300,000 EUR
Moldova	Agentia Nationala Pentru Cercetare Si Dezvoltare	ANCD	100,000 EUR
Netherlands	The Netherlands Organisation for Health Research and Development	ZonMw	1 M EUR
Norway	The research Council of Norway	RCN	600,000 EUR



<i>Country</i>	<i>Funding Partner Organisation</i>	<i>Acronym</i>	<i>Contribution</i>
Poland	National Science Centre	NCN	500,000 EUR
Spain	Instituto de Salud Carlos III	ISCIII	1 M EUR
Sweden	Swedish Research Council	SRC	15 M SEK
Switzerland	Swiss National Science Foundation	SNSF	600,000 EUR
United Kingdom	UKRI Research Councils	UKRI	2 M EUR

### **3.5 Contact persons**

The only official communication line is between the Joint Call Secretariat (JCS) (Chief scientist office, Israel ministry of health: [JPIAMR@moh.gov.il](mailto:JPIAMR@moh.gov.il)) and the project coordinator. Throughout the application procedure, the Joint Call Secretariat will contact the project coordinators, who must forward all information to other partners of their consortia. Each FPO has national contact persons who can be contacted for information about the specific national requirements (see the contact list in Annex A).

Please note that country-specific requirements might apply to this call. Compliance with the national or institutional regulations specified in Annex B is mandatory. Applicants are strongly advised to contact their national FPO (see Annex A) prior to submitting a pre-proposal.

## **4. Evaluation**

Submitted eligible pre- and full proposals will be remotely evaluated by international experts. International experts will discuss the remote evaluation results in the peer review meeting, agree on a consensus evaluation, and recommend the pre-proposals that could be invited to submit a full proposal or the full proposals that could be recommended for funding depending on the evaluation stage.

Pre-proposals and full proposals will be assessed according to specific evaluation criteria listed below.

In the full proposal stage, if you are conducting an interventional study, additional information will be requested on the proposed methodology (will the study design and methodology answer the research question) and the feasibility of the study to deliver results (are study resources sufficient and reasonable to deliver on time and target whilst ensuring good research governance).

The adequacy of the proposals submitted to the call will be assessed by the evaluation panel. Proposals not relevant to the call topics and objectives will not be invited to submit a full proposal, regardless of their scientific quality.

A scoring system from zero (0) to five (5) will be used to evaluate the proposal's performance with respect to the evaluation criteria given in section 4.1 .

#### 4.1 Scoring system

**0: Failure.** The proposal fails to address the criterion in question or cannot be judged because of missing or incomplete information.

**1: Poor.** The proposal shows serious weaknesses in relation to the criterion in question.

**2: Fair.** The proposal generally addresses the criterion, but there are significant weaknesses that need corrections.

**3: Good.** The proposal addresses the criterion in question well, but a number of improvements are possible.

**4: Very good.** The proposal addresses the criterion very well, but minor improvements are possible.

**5: Excellent.** The proposal successfully addresses all aspects of the criterion in question; there are no suggestions for improvement.

#### 4.2 Proposal evaluation criteria

##### 1. Excellence

Criterion	For pre-proposal	For full proposal
a. Clarity and pertinence of the objectives.	X	X
b. Credibility of the proposed approach and methodology, in relation to the research objectives.	X	X
c. Soundness and research base of the concept.	X	X
d. Novelty, ambition, timeliness, and innovation.	X	X
e. Scientific excellence of the consortium	X	X
f. Fit the scope of the call	X	X

##### 2. Impact

Criterion	For pre-proposal	For full proposal
a. Impact of the proposal to prevent or mitigate fungal infections <b>Or</b> Impact of the proposal to prevent or reduce the emergence or spread of antibacterial or antifungal resistance and to guide new policies against antimicrobial resistance	X	X
b. Potential of the expected results for clinical, public health, animal, or plant health, or environmental benefit (including economic viability where appropriate) and/or other socioeconomic health interventions	X	X
c. Added value of transnational collaboration and potential for fostering a longer-term international network of researchers. For example, bringing together specific know-how and/or innovative technologies, gathering a critical mass of patients or biological material, sharing of resources (models, databases, biobanks, etc.), and international comparisons.	X	X
d. Potential reach of the project results, including dissemination and communication measures. Accessibility of the proposed innovative strategy (different geographical areas, different populations.)		X
e. Appropriateness of end user and stakeholder participation/engagement, for example, policy makers, industry, patient organisation, health and veterinary care, farmers, etc.		X

### 3. Quality and efficiency of the implementation

Criterion	For pre-proposal	For full proposal
a. Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks within the given timeframe.	X	X
b. Adequate distribution of the tasks between the project partners considering the required expertise	X	X
c. Strength of the transnational collaboration (balanced geographical distribution of the tasks)	X	X
d. Incorporation of social, gender, equity, economic considerations and cultural sensitivity dimensions into the proposed research	X	X
e. Quality of the proposed Open Science practices, data management, Intellectual Property management, and Freedom to Operate where appropriate.		X
f. Appropriateness of the management and governance structures and procedures, including risk and innovation management.		X
g. Potential exploitation and relevance of the outcomes of the findings beyond the current project. (long-term strategy)		X
h. Contingency plan, including risk assessment and mitigation (including of unforeseen circumstances like Covid-19).		X
i. Justification of the requested budget and cost-effectiveness of the project (appropriate distribution of resources in relation to project's activities, project partner responsibilities and time frame).		X

Evaluation scores will be awarded for the three main criteria, and not singularly for the different aspects listed below the criteria, although these different aspects will be taken into account in scoring the main criteria. In order for an application to be considered fundable, the threshold score for individual criteria is set at three (3) (of a maximum of five (5)). The overall threshold for the score for all three criteria together is set at nine (9). The maximum score that can be reached from all three criteria together is 15 points.

#### 4.3 Ethics and legal requirements

Proposals selected for funding will undergo an ethics review by the Ethics Panel. At the full proposal stage, in addition to the scientific content and if relevant, a full description of stakeholder engagement (or a justification if this is not applicable), safety, animal studies, genetically modified organisms and microorganisms, environmental hazards and waste handling, data management, statistical methods, ethics and legal issues will be required. Applicants should anticipate this requirement and ensure that they have consulted with relevant experts to verify the feasibility of the project, and that the proposal can be completed within the defined budget and within the prescribed time window. In the full proposal template, a self-assessment checklist must be completed.

Each funded consortium must have all necessary ethics approvals for research on animals, and/or research involving human subjects or data/samples obtained from human subjects according to national/regional law and regulation and in compliance with EU Horizon 2020 rules before initiation of such research. Applications for ethics approval should be made available immediately to the JPIAMR secretariat upon request. JPIAMR may perform an ethics review of the research at any time (evaluation and/or follow-up of the funded projects).

Project coordinators must inform the JPIAMR secretariat as well as the FPOs supporting the project if ethics approvals are denied. The notification should be communicated no more than 2 weeks after the rejection and the proposed rescue plan (new request for ethics approval, modification of the work plan/ project scope) must be approved by the FPOs supporting the project.

Any project partner of a consortium in breach of research ethics regulations will subject the whole project for re-evaluation by all FPOs of the project resulting in potential inhibition of all activities, withdrawal of funds, cancelling of contracts, and /or legal action or other sanctions according to national law.

#### **4.4 Social and gender equity, cultural sensitivity, and economic viability**

It is important that consortia and research proposals are founded upon principles of social and gender equity, cultural sensitivity, and economic viability. Consortia are highly encouraged to apply these principles to the composition, leadership, and management of research projects.

Where relevant, research projects are expected to apply an intersectional and multi-dimensional approach by integrating sex, gender, and other individual and population-level determinants of health (such as age, socio-economic status, ethnicity) into the project's design, implementation, monitoring, evaluation, and knowledge translation activities.

Research projects are expected to consider individual and population-level determinants of health when collecting and analysing data to design and/or implement interventions in ways that are accessible and affordable to target beneficiaries, to systematically capture and report on sex, gender, and other relevant factors in the project research outputs, and to meaningfully engage the participation of targeted marginalised groups in the research activities.

## **5. Decision of project to be funded**

After peer review of the pre-proposals, selected consortia will be invited to submit a full proposal by email from the Joint Call Secretariat. The final funding decision will be taken by the Call Steering Group based on the review and the recommendation by the Peer Review Panel and will be subject to budgetary considerations and ethics review.

## **6. Reporting requirements and other obligations of JPIAMR grantees**

Overall project monitoring will be the responsibility of the JPIAMR secretariat. On behalf of the project consortium, the Project coordinator is required to submit reports to JPIAMR according to the Monitoring policy for JPIAMR funded projects and networks. The following must be submitted:

- a mid-term report, on behalf of the consortium, 18 months after the project starts;
- a final report on research completed by the consortium, on behalf of the consortium, within 2 months of the end of the project;
- an ex-post report three years after the closure of the project.

The monitoring outcomes will be collected and made accessible to all funding organisations. In addition, the monitoring of each funded project may also be done through review seminars. The JPIAMR secretariat will contact the project coordinator one month in advance of reporting deadlines and provide them with a link to the JPIAMR reporting system.

Outside of the above-listed reports, grantees have an obligation to supply the JPIAMR with updated information of the consortium and its results, if requested.

## 7. Intellectual Property

The ultimate goal of Joint Programming is to bring together national research efforts in order to make better use of public R&D resources and to tackle common global challenges more effectively in selected key areas.

For Joint Programming activities to contribute effectively to socioeconomic progress, the results of the research activities must be exploited. This requires appropriate identification and protection of the intellectual property being generated and effective knowledge transfer. Any particular protection and exploitation strategy should be agreed before the research activities start. The ten principles of Socially Responsible Licensing (SRL) should be part of this strategy.

Depending on the nature of the research and on the interests of the different parties, if there are opportunities for exploitation, it is recommended that parties decide in advance on either adopting a common exploitation strategy or leaving exploitation of results to the party best placed to commercialise it, with appropriate compensation mechanisms for the contributing parties. Please see section 8 for a link to a simplified consortium agreement template, available on the DESCA website. National rules and regulations may apply, please consult Annex B.

## 8. Project partner Consortium Agreement

The consortium partners of each funded project are required to set up and sign a project partner consortium agreement (PCA) in order to deal with any other issues related to the role, tasks and responsibilities within the consortium, the protection of intellectual property, and where applicable how the consortium will address the ten principles of SRL. The PCA needs to be in accordance with the national funding rules of the respective Funding Partner organisations - see Annex B. Upon request, this consortium agreement must be made available to the concerned Funding Organisations.

The PCA must address (as a minimum), the following points:

- common start date and duration of the research project and the duration of the PCA;
- organisation and management of the project;
- role, tasks, and responsibilities of each project partner;
- the resources and funding;
- confidentiality and publishing;
- Intellectual Property Rights (if applicable);
- how the ten principles of Socially Responsible Licensing will be addressed (if applicable);
- decision making within the consortium;
- handling of internal disputes;
- the liabilities of the research partners towards one another (including the handling of default of contract).

Any issues regarding funding are a bilateral matter between each project partner and the relevant FPO should be excluded from the PCA. The PCA together with any other information required by national/regional regulations must be made available on request to the national funding organisations and the JPIAMR secretariat.

Please see the [DESCA website](#) for further information on the development of a simplified consortium agreement under the Horizon 2020 Framework.

## 9. Open access and FAIR data

Following the ambitions of open access, researchers involved in JPIAMR funded projects must ensure that science and society can be made aware of the information about the project as early as possible in the research process.

In cases where there is information that cannot be shared (either by open access publication, or by sharing of data or biological materials), this must be explained, and substantiated in the JPIAMR reporting (e.g. temporary confidentiality may be accepted in the case of commercial exploitation).

### Publications (open access):

Unless it goes against their legitimate interests, each beneficiary must — as soon as possible — disseminate its results by disclosing them to the public by appropriate means (other than those resulting from protecting or exploiting the results), including in scientific publications (in any medium).

The JPIAMR promotes Green, Diamond and Gold Open Access measures, as recommended by the “[Guidelines to the Rules on Open Access to Scientific Publications and Open Access to Research Data in Horizon 2020](#)” (version 3.2 of March 21, 2017). Each participant may also be required to comply with the Open Access policy of its funding organisation (See country-specific information in Annex B).

In the context of the JPIAMR, the following policy applies:

- Publishing costs in an open access context, related to scientific results obtained in the context of a JPIAMR project, are considered eligible unless national funding regulations state to the contrary (see country-specific requirements in Annex B).
- Authors are encouraged to retain their copyright or, in case of transfer of copyright to third parties, at least to retain the right to disseminate via open access. National funding regulations may apply (see country-specific requirements in Annex B).

### Research data:

JPIAMR requires grant holders to make their data as much Findable, Accessible, Interoperable, and Reusable (FAIR) as possible. FAIR data may also be open data, however, restricted access to FAIR data is also possible. FAIR data allow researchers to verify research results and reuse data in future research. FAIR research data can typically be accessed, mined, exploited, reproduced, and disseminated: under certain conditions, or free of charge for the user (=open).

Also biological materials (biospecimens, microbial strains/samples, molecular derivatives) need to be FAIR. This may be done by describing the biomaterials with metadata (and these are digital).

In the context of the JPIAMR, the following policy applies:

- JPIAMR expects researchers to create reusable research data and biological materials, and to maximize the opportunities to make the research data generated from their scientific work available.
- In case that data originates from ongoing projects, the funding conditions related to those projects needs to be taken into account. These conditions cannot be overruled by conditions for new projects.
- At the end of the project, the consortium needs to provide information on how the data and/or biological materials can be found (e.g., catalogue), where they are stored (repository), the conditions for access or use to the resources (e.g., open or restricted access).

What needs to be done in the application phase?

- Check the requirements for data management and data sharing of the relevant national funder.
- Plan the collection of research data, and biomaterials. Start planning a Data Management Plan (DMP); consult a data expert; look for services from research infrastructures.
- Search for reusable data and biomaterials; ask for permission to use these.
- Take costs for data management and infrastructure into account when planning the budget.

For further information, please consult:

- JPIAMR website
- the Science Europe “Practical Guide to the International Alignment of Research Data Management”(RDM) with (1) core requirements for data management, allowing funders and research institutes to align their RDM requirements and template; (2) criteria for the selection of trustworthy repositories for storing and sharing research data <https://www.scienceeurope.org/our-resources/practical-guide-to-the-international-alignment-of-research-data-management/>
- the Horizon 2020 “Guidelines on Open Access to Scientific Publications and Research Data in Horizon 2020” with indications on how researchers can comply with their responsibilities regarding research data quality, sharing and security: [http://ec.europa.eu/research/participants/data/ref/h2020/grants\\_manual/hi/oa\\_pilot/h2020-hi-oa-pilot-guide\\_en.pdf](http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-pilot-guide_en.pdf)
- the BBMRI services for ethical, legal and societal issues (ELSI) <https://www.bbmri-eric.eu/services-support/>

## 10. General Data Protection Regulation (GDPR)

Personal information provided by an applicant will be processed in accordance with article 6.1 (c) or 6.1 (e) of the General Data Protection Regulation (GDPR) (2016/679) and for the purposes of:

- processing and evaluating the pre- and full proposal where processing shall be lawful only if and to the extent that processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller;
- administering any subsequent funding award;
- managing the relationship between the applicant and the Funding Partner Organisations;
- analysing and evaluating the call;
- providing aggregate data to national and European surveys and analyses on the funded projects;
- complying with audits that may be initiated by the Funding Partner Organisations and the European Commission (or its agencies).

In addition, by submitting an application (pre- and full proposal) to the IMPACT 2024 Call, the applicants agree to share their personal data with FPOs based outside the European Economic Area (see table on p. 17) and with third parties such as evaluators (some of which may be based outside the European Economic Area) in relation to the above activities.

Data protection in countries outside the European Economic Area (FPOs participating in the call)

Personal data protection laws <b>comparable</b> to those of EU law (adequacy decisions issued by the European Commission)	Personal data protection laws <b>not comparable</b> to those given by EU law
Israel (CSO-MOH)	Australia (NHMRC)
Switzerland (SNSF)	Canada (CIHR)
the United Kingdom (UKRI)	Moldova (ANCD)

Funding Partner Organizations and third parties may link the data that applicants provide in the application with national, bibliographic or external research funding data which is available through public subscription-based databases (e.g. Scopus, Web of Science) or other national/open datasets.

## 11. Privacy

Responding to a JPIAMR call for proposals, both as project coordinator or project partner, gives JPIAMR and Funding Partner Organisations the right to use and store the information submitted for analysis of the call success rate, national response rate, etc. Information will only be shared between the Funding Partner Organisations and the JPIAMR secretariat, except for consortia including project partners applying for funding from a Swedish FPO (SRC). For those consortia, the applications (pre- and full proposals) may be made available upon request after the respective call deadlines.

Accepting a JPIAMR grant award and associated grant contract from a national funding organisation gives JPIAMR and Funding Partner Organisations the right to store, share, and analyse information on beneficiaries and consortia (rules may differ between different countries). Composition of the awarded consortia (Principal investigators, Institution) as well as the title, acronym and abstract of funded projects will be published and openly accessible. No data will be shared with third parties or commercial entities without the formal consent of the project coordinators, except for consortia including project partners applying for funding from a Swedish Funder (SRC). For those consortia, the applications (pre- and full proposals) may be made available upon request after the respective call deadlines.

## 12. Acknowledgements

All results disseminated by the funded projects (in any form, including electronic) should acknowledge funding from the JPIAMR and include the following text: *This project (project acronym/name) has been supported by (name of the national funder) under the framework of the JPIAMR - Joint Programming Initiative on Antimicrobial Resistance.*



## Annex A: National contact persons for each party providing funding

### JPIAMR IMPACT JOINT CALL SECRETARIAT (JCS)

Chief scientist office, Israel ministry of health (CSO-MOH)

Contact persons:

Ronit Meyuhas; Irit Allon

e-mail: [JPIAMR@moh.gov.il](mailto:JPIAMR@moh.gov.il)

Tel. +972 2 5082159/2167

Country	Funding org.	Contact person(s)	Email	Telephone
Australia	NHMRC	Kirilly Agnew Jane Lofts	<a href="mailto:international@nhmrc.gov.au">international@nhmrc.gov.au</a>	+61 2 6217 9451
Belgium	FRS FNRS	Agnès Roba Florence Quist	<a href="mailto:international@frs-fnrs.be">international@frs-fnrs.be</a>	+32 (0)2 504 92 36 +32 (0)2 504 93 51
Canada	CIHR	Contact Centre	<a href="mailto:support-soutien@cihr-irsc.gc.ca">support-soutien@cihr-irsc.gc.ca</a>	+1 613-954-1968 1-888-603-4178
France	ANR	Sophie Gay	<a href="mailto:JPI-AMRCalls@agencerecherche.fr">JPI-AMRCalls@agencerecherche.fr</a>	+33 1 78 09 80 39
Germany	DLR	Barbara Junker Akin Akkoyun	<a href="mailto:Barbara.junker@dlr.de">Barbara.junker@dlr.de</a> <a href="mailto:Akin.akkoyun@dlr.de">Akin.akkoyun@dlr.de</a>	+49 228 3821 1274 +49 228 3821 1864
Hungary	NKFIH	Klára Horváth	<a href="mailto:klara.horvath@nkfi.gov.hu">klara.horvath@nkfi.gov.hu</a>	
Ireland	HRB	Amanda Daily, Siobhan Hackett	<a href="mailto:Amanda.Daly@hrb.ie">Amanda.Daly@hrb.ie</a> <a href="mailto:shackett@hrb.ie">shackett@hrb.ie</a>	
Israel	CSO-MOH	Ronit Meyuhas Irit Allon	<a href="mailto:Ronit.meyuhas@moh.gov.il">Ronit.meyuhas@moh.gov.il</a> <a href="mailto:Irit.allon@moh.gov.il">Irit.allon@moh.gov.il</a>	+97225082159 +97225082167
Italy	FRRB	Paola Rebagliati Erica Torti	<a href="mailto:progetti@frrb.it">progetti@frrb.it</a>	+ 39 02 67650174
Italy	It-MOH	Maria Jose Ruiz Alvarez	<a href="mailto:mj.ruizalvarez-esterno@sanita.it">mj.ruizalvarez-esterno@sanita.it</a>	+ 39 06 5994 3214 / 06 49906836
Latvia	LCS	Uldis Berkis	<a href="mailto:Uldis.Berkis@lzp.gov.lv">Uldis.Berkis@lzp.gov.lv</a>	+371-29472349
Lithuania	LMT/RCL	Živilė Ruželė	<a href="mailto:Zivile.ruzele@lmt.lt">Zivile.ruzele@lmt.lt</a>	+37067614383

Country	Funding org.	Contact person(s)	Email	Telephone
Moldova	ANCD	Viorica Boaghi Sveatoslav Postoronca	<a href="mailto:Viorica.boaghi@ancd.gov.md">Viorica.boaghi@ancd.gov.md</a> <a href="mailto:Sveatoslav.postoronca@ancd.gov.md">Sveatoslav.postoronca@ancd.gov.md</a>	+373 22 272339 +373 22 294861
Netherlands	ZonMw	Linda van Gaalen Nora Wolff Anouk Warmerdam	<a href="mailto:jpiamr@zonmw.nl">jpiamr@zonmw.nl</a>	
Norway	RCN	Alexandra Bjørk-Skaflestad	<a href="mailto:alb@forskningsradet.no">alb@forskningsradet.no</a>	
Poland	NCN	Monika Pobiega Jolanta Palowska	<a href="mailto:JPI.AMR@ncn.gov.pl">JPI.AMR@ncn.gov.pl</a>	+48 123 419 176 +48 695 211 478
Spain	ISCIII	Cándida Sanchez Barco	<a href="mailto:cbarco@isciii.es">cbarco@isciii.es</a>	+34 918222063
Sweden	SRC	Kristian Haller	<a href="mailto:Kristian.haller@vr.se">Kristian.haller@vr.se</a>	+46 8 546 12 307
Switzerland	SNSF	Beatrice Schibler Clémence Le Cornec	<a href="mailto:amr@snf.ch">amr@snf.ch</a>	+41 31 308 22 22
United Kingdom	UKRI	Danielle Sagar Stephen Webb	<a href="mailto:UKRI-AMR@ukri.org">UKRI-AMR@ukri.org</a>	

## Annex B: National Rules and Requirements

**Important note to applicants:** Applications to JPIAMR joint transnational calls can require the submission of additional information on national funding platforms. All applicants must have fulfilled both joint and national requirements for an application to be eligible.

This is only a summary. Refer to national websites and contact the respective contact person for full details.

Australia – NHMRC National Health and Medical Research Council	
<b>Specific National/ Regional rules</b>	<p>Institutions must be a NHMRC Administering Institution to be eligible to receive and administer NHMRC funding.</p> <p>Applications for NHMRC funding are subject to the general eligibility requirements as set out in the <i>JPIAMR: Interventions Moving forward to Promote ACTION to counteract the emergence and spread of bacterial and fungal resistance and to improve treatments</i> Grant Opportunity Guidelines when available and within the <u>NHMRC Funding Agreement</u>. Applicants should read all relevant reference material.</p> <p>Applicants from Australia intending to apply for funding via NHMRC should notify the national contact point by email to signal an intention to join a consortium, via <a href="mailto:international@nhmrc.gov.au">international@nhmrc.gov.au</a>.</p>
<b>Eligible costs</b>	<p>Refer to NHMRC Direct Research Costs guidelines: <a href="http://www.nhmrc.gov.au/funding/manage-your-funding/funding-agreement">www.nhmrc.gov.au/funding/manage-your-funding/funding-agreement</a></p> <p>There is no minimum value for grants funded through this grant opportunity. The amount of funding for each JPIAMR grant will be based on assessment of the requested budget. Applications must clearly justify the requested duration and budget and how they will support the proposed outcomes of the research. Internal NHMRC budget review will consider this information and NHMRC may alter the duration and/or budget to ensure the research aims and objectives can be achieved while ensuring value with money. An altered budget does not alter the scope of the proposed research activity.</p>
<b>Additional documents required</b>	Full proposals to be submitted through the NHMRC grant management system (Sapphire)
<b>Eligible One Health settings</b>	Projects addressing human health and environment (where relevant to human health) will be eligible for funding. NHMRC will not fund projects that do not include human health research activities.
<b>Eligible experimental approaches</b>	All types of studies or experimental approaches are admissible.
<b>Further information</b>	<p>The total provisional funding allocation for this funding call is \$3 million AUD. The NHMRC funding allocation will be distributed to successful grants until the \$3 million funding allocation is exhausted. NHMRC's Research Committee reviews and advises indicative budget amounts to be awarded across individual funding schemes annually.</p> <p>Australian applicants should refer to the <u>NHMRC website</u> and <u>GrantConnect</u> for specific information on this Grant Opportunity when it becomes available.</p> <p>NHMRC funding is subject to governmental approval processes.</p>

Belgium – F.R.S.-FNRS Fonds de la Recherche Scientifique - FNRS	
<b>Specific National/ Regional rules</b>	All eligibility rules and criteria can be found in the <a href="#">PINT-MULTI regulations</a> .
<b>Eligible costs</b>	All eligibility rules and criteria can be found in the <a href="#">PINT-MULTI regulations</a> . <b>“Overhead” is not an eligible cost.</b> If the project is selected for funding, these costs will be subject to a separate agreement between the institution of the beneficiary and the F.R.S.-FNRS.
<b>Additional documents required</b>	Applicants to F.R.S.-FNRS funding must provide basic administrative data by submitting an administrative application on <a href="#">e-space</a> <u>within 5 working days after the general deadline of the JPIAMR call to be eligible</u> . Please select the “PINT-MULTI” funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS.
<b>Eligible One Health settings</b>	All 3 research areas (Human Health, Animal Health and Environment Health) are eligible for funding.
<b>Eligible experimental approaches</b>	Clinical studies are <b>not</b> eligible for funding by the F.R.S.-FNRS.
<b>Further information</b>	Additional national eligibility criteria for the proposal beyond the general criteria of the joint call: <ul style="list-style-type: none"> <li>• Basic research (low Technology Readiness Level) carried out in a research institution from the “Fédération Wallonie-Bruxelles”</li> <li>• The F.R.S.-FNRS will not fund clinical research</li> </ul> The F.R.S.-FNRS will not fund industrial partners or any activity related to the private sector

Canada – CIHR Canadian Institutes of Health Research	
<b>Specific National/ Regional rules</b>	<p>Among eligible organisations that CIHR may fund are non-governmental organisations with a research or knowledge translation mandate. Details regarding eligible applicants for a given competition will be specified in the funding opportunity on <a href="#">ResearchNet</a>.</p> <p>Individuals in the Nominated Principal Applicant role must be affiliated with a <a href="#">CIHR eligible Canadian postsecondary institution and/or their affiliated institutions</a>; individuals working with municipal, provincial, and/or territorial governments are also eligible where the research proposed is not already funded by that Government of Canada sector.</p> <p>Individuals in the Nominated Principal Applicant role must have their substantive role in Canada for the duration of the requested grant term. Note that CIHR is not prescriptive regarding the duration of time that a NPA must physically reside in Canada, as this falls under the purview of applicable policies of the administering institution, employment terms and conditions, and or collective agreements</p> <p>Appointments and/or positions that can be renewed prior to the end of the requested grant term are eligible at the discretion of the administering institution.</p> <p>CIHR grants and awards are paid to <a href="#">CIHR-eligible institutions</a>, through a CIHR account, from which the Nominated Principal Applicant draws funds.</p>

	<p>Canadian applicants must complete a CIHR application and submit it using ResearchNet in addition to the proposal submitted to the Joint Call Secretariat.</p> <p>Canadian applicants must submit an Operating Budget for the project, with the amounts quoted in Canadian dollars, and a complete justification for funds requested using ResearchNet in addition to the proposal submitted to the Joint Call Secretariat. The deadline for submission of this application is the same as the proposal deadline to the Joint Call Secretariat.</p> <p>Projects receiving a CIHR grant must comply fully with the <a href="#">CIHR Funding Policies</a>. Policies and guidelines cover areas such as Applicant Responsibilities, Official Languages policy, Access to Information and Privacy Acts. For more information, please refer to <a href="#">Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2)</a> and <a href="#">Tri-Agency Framework: Responsible Conduct of Research</a>.</p> <p>To complete the ResearchNet application for funding you must include your personal information. CIHR will collect, use, retain and dispose of your personal information in accordance with the <i>Access to Information and Privacy Act</i>. If applicable, the information provided may be shared, in whole or in part, with CIHR Institute Staff. CIHR will not share the information collected through your abbreviated application in CIHR ResearchNet with other institutions or signatories to the JPIAMR.</p> <p>Funding applications submitted to JPIAMR will be held in jurisdictions outside of Canada and will not be subject to the provisions of the Privacy Act. Information submitted to JPIAMR as part of the applications will be governed by the provisions of EU data protection laws, the European Data Protection Regulation (GDPR). Please note that all parties on applications must also comply with (GDPR) (2016/679).</p> <p>Canadian applicants do NOT need to submit the pre-proposal through CIHR ResearchNet, ONLY the full proposal.</p>
<p><b>Eligible costs</b></p>	<p>Applicants should review the <a href="#">Use of Grant Funds Section of the Tri-Agency (CIHR, NSERC and SSHRC) Guide on Financial Administration</a> for a complete listing and description of allowable costs and activities.</p>
<p><b>Additional documents required</b></p>	<p>Applications submitted to CIHR require applicant consent and institutional approval (if applicable) to the use and disclosure of full application and nominative information for relevance review and funding decisions at the time of application.</p> <ul style="list-style-type: none"> <li>• The applicant will be required to submit to all JPIAMR reporting requirements.</li> <li>• The Nominated Principal Applicant will be required to submit an Electronic Final Report to CIHR. This online report will be made available to the Nominated Principal Applicant on ResearchNet at the beginning of the grant funding period and can be filled in as the research progresses.</li> <li>• All reports may be shared with partners supporting the grant.</li> <li>• The Nominated Principal Applicant must have successfully completed one of the <a href="#">sex- and gender-based analysis training modules</a> available online through the CIHR Institute of Gender and Health and have submitted a Certificate of Completion (see How to Apply section). Select and complete the training module most applicable to your research project. Applicants are encouraged to review the "<a href="#">How to integrate sex and gender in research</a>" section on the CIHR website.</li> </ul> <p>CIHR is committed to promoting the inclusion and advancement of groups underrepresented in science as one of the means to enhance excellence in</p>

	<p>research, training and knowledge translation. CIHR's position on equity, diversity and inclusion (EDI) is available in the <a href="#">Tri Agency Statement on Equity, Diversity and Inclusion</a>. Additional guidance can be found on <a href="#">the Best practices in Equity, Diversity and Inclusion in Research webpage</a>.</p> <p>It is noted that CIHR does not retain or claim any rights to IP in relation to research that it funds. Accordingly, the Canadian researchers retain full freedom in negotiating the Partner Consortium Agreement (PCA) required, including whether or not to accept the IP conditions. The Nominated Principal Applicants do NOT need to send a signed copy of the PCA to CIHR.</p>
<b>Eligible One Health settings</b>	Projects addressing human health will be eligible for funding. CIHR will NOT be funding projects on animal health, plants, food, and/or environment that do not include human health research activities.
<b>Eligible experimental approaches</b>	Projects involving pre-clinical studies are eligible under this Funding Opportunity.
<b>Further information</b>	<p>The total amount available for the Canadian component is \$600,000 CAD, enough to fund the Canadian component of up to 1 joint transnational team:</p> <p>The Canadian Consortium Coordinator can receive up to CAD \$200,000 per year for three (3) years for a maximum of CAD \$600,000 for the Canadian component of the joint transnational team. The Canadian Consortium Partner can receive up to CAD \$166,667 per year for three (3) years for a maximum of CAD \$500,000 for the Canadian component of the joint transnational team.</p> <p>The proposals will be funded based on the ranking list recommended by the Peer Review Panel and decided by the Call Steering Group. The final funding decision will be made by the national/regional funding organizations and will be subject to budgetary considerations with the goal of optimal usage of the available budget. Approved joint transnational teams may receive an across-the-board cut to the budget, if necessary, to maximize the number of funded opportunities. For full details of CIHR's requirements, please refer to the Funding Opportunity on ResearchNet.</p>

<b>France – ANR French National Research Agency</b>	
<b>Specific National/ Regional rules</b>	<p>ANR may fund research organisations and undertakings.</p> <p>As for research organisations, only those that have their primary establishment in France may be funded. As for undertakings, those that have their real head office in an EU member State and an establishment (primary or secondary) in France may be funded.</p> <p>Within this framework, research institutions such as EPST, EPIC, Universities, Hospitals, Foundations, as well as companies and NGOs (<i>associations</i>) can apply. This list is not comprehensive and funding rates vary. Please fill the <a href="#">form related to economical activities</a> to identify your funding rate and consult the “<i>règlement financier</i>” (<a href="http://www.agence-nationale-recherche.fr/RF">http://www.agence-nationale-recherche.fr/RF</a>) for more details.</p> <p>Please note that companies with <a href="#">economic difficulties</a> cannot receive ANR funding.</p> <p>Countries subject to sanction(s) by the European Union authorities are excluded from this call. At the time of publication, these countries include the following: Belarus, Russia. If entities from these countries are Partners in an application in which some Partners request ANR support, the latter will be</p>

	deemed ineligible by ANR. This list might evolve and application measures be taken accordingly.
<b>Eligible costs</b>	<p>Except where specified in the Call text or in the “<i>Modalités de participation</i>”, standard ANR funding rules apply for eligible costs. These rules are specified in ANR’s “Règlement financier” mentioned above and in an explanatory note available at: <a href="https://anr.fr/fr/rf/fiche-couts/">https://anr.fr/fr/rf/fiche-couts/</a></p> <p>Eligible costs (e.g.: personnel costs of non-permanent researchers, costs of instruments and equipment, additional overheads and other operating expenses incurred directly as a result of the research project such as, for instance: travel costs) and funding rates vary based on the type of research, type of research partners and composition of the consortium. Please note that expenses related to permanent staff are not eligible for the beneficiaries “à coût marginal”. For the Beneficiaries “à coût marginal”, please note that, in 2024, overheads correspond to <b>14,5%</b> of the total eligible costs (11% dedicated to “tutelle gestionnaire” and 3,5 % to the laboratory).</p> <p>Double funding of research projects is not permitted. ANR will perform cross-checks of submissions against other joint transnational (JPIAMR, EUP AH&amp;W...) and national calls (including AAPG and the PPR “antibiorésistance”). Partners may not apply for funding for the same research activities in different calls. In addition, there can be no double funding for activities already funded by EC H2020 and Horizon Europe calls. In case of any doubts, please contact your national contact point <u>before</u> submission.</p>
<b>Additional documents required</b>	No additional documents should be submitted to ANR during the submission phase. If a project is selected for funding, French partners will have to fill administrative and financial data on the ANR platform.
<b>Eligible One Health settings</b>	All research areas (Human Health, Animal Health, Plants, Food and the environment) are eligible for funding.
<b>Eligible experimental approaches</b>	All approaches and research disciplines are eligible with the exception of phase III clinical trials.
<b>Eligible Early Stage Researchers</b>	To be eligible for this call as Principal Investigator, early stage researchers must hold a research position in an eligible institution covering the duration of the project. The salary of the Early Stage researcher will not be covered by the present grant. Early stage researchers who will apply to this call as Principal Investigator must imperatively send the documents (working contract covering the duration of the project, chair announcement covering the duration of the project, commitment of the employer) proving their eligibility by mail to the ANR contact point ( <a href="mailto:JPI-AMRCalls@agencerecherche.fr">JPI-AMRCalls@agencerecherche.fr</a> ) before the closing of the call. Early stage researchers do not need to head their own lab, or group while applying. If an early stage researcher does not head its own research group/lab, the signature of the head of the department should be included in the letter of intent, even at the pre-proposal stage.
<b>Further information</b>	<p><b>Maximum amount per project:</b> 450 000 €</p> <p><b>Maximum funding per partner:</b> 250 000 € (Increased to 330 000 € for coordinators)</p> <p><b>Minimum amount per partner:</b> 15 000 €</p>

	<p>More details for the participation of French partners (“<i>Modalités de participation</i>”) at <a href="https://anr.fr/fileadmin/aap/2024/aap-jpiamr-2024-annexe-fr.pdf">https://anr.fr/fileadmin/aap/2024/aap-jpiamr-2024-annexe-fr.pdf</a>.</p> <p>If applicable, Declarations of Due Diligence for the funded projects (Nagoya Protocol) must be transmitted to ANR in due time.</p> <p>In case of a conflict of interpretation between the terms and conditions stated in this annex and the “<i>Modalités de participation</i>” and “<i>Règlement financier</i>”, the latter shall prevail.</p>
--	---

<b>Germany – DLR</b> <b>Deutsches Zentrum fuer Luft – und Raumfahrt Ev</b>	
<b>Specific National/ Regional rules</b>	<p>Legal bodies:</p> <ul style="list-style-type: none"> <li>• Universities</li> <li>• University hospitals</li> <li>• Non-university research institutes</li> <li>• Industry</li> </ul> <p>Note: industry is funded with a maximum of 50-60% of their costs.</p>
<b>Eligible costs</b>	<p>Personnel, Consumables, Animals, Subcontracts, Equipment, Travel, Overheads.</p> <p>Overheads refer to “Gemeinkosten” (applicable e.g. for Helmholtzcentres and Fraunhofer-Society) as well as “Projektpauschale” (applicable for universities and university hospitals).</p> <p>Individual project coordinators/partners may request up to 300 000 Euro including overheads. A project consisting of two German partners may request a maximum of 500 000 Euro including overheads.</p> <p>For further details please refer to the national guidelines “BMBF Formularschrank”</p>
<b>Additional documents required</b>	No
<b>Eligible One Health settings</b>	All
<b>Eligible experimental approaches</b>	All
<b>Further information</b>	For further details on the later formal application please refer to the national guidelines “ <a href="#">BMBF Formularschrank</a> ”

<b>Hungary – NKFIH</b> <b>National Research, Development and Innovation Fund</b>	
<b>Specific National/ Regional rules</b>	<p>Eligible institutions:</p> <p>Eligible applicants from Hungary are entities falling under any of the following GFO codes:</p> <ul style="list-style-type: none"> <li>• enterprise with legal entity (GFO code: 11X)</li> <li>• non-profit organisation with legal entity (GFO code: 5XX)</li> <li>• budgetary units and entities (eg. higher education institutions, municipalities;) (GFO code: 3XX)</li> <li>• enterprise with a registered office in the European Economic Area and a branch in Hungary (GFO: 226).</li> </ul> <p>(The Guide for Applicants for the 2019-2.1.7-ERA-NET national call is applicable.)</p>



<b>Eligible costs</b>	All research-related costs in accordance with government decree 380/2014 (XII.31) are eligible. In case a partner is subject to State Aid rules, funding intensity shall be set at a level that complies with the State Aid rules in force at the time of the funding decision (The Guide for Applicants for the 2019-2.1.7-ERA-NET national call is applicable.)
<b>Additional documents required</b>	No
<b>Eligible One Health settings</b>	All One Health settings are eligible.
<b>Eligible experimental approaches</b>	No particular conditions.
<b>Further information</b>	<a href="https://nkfi.gov.hu/palyazoknak/nkfi-alap/era-net-ejp-cofund-2019-217-era-net/palyazati-felhivas-2019-217-era-net">https://nkfi.gov.hu/palyazoknak/nkfi-alap/era-net-ejp-cofund-2019-217-era-net/palyazati-felhivas-2019-217-era-net</a>

<b>Ireland – HRB Health Research Board</b>	
<b>Specific National/ Regional rules</b>	Applicants based in Ireland and seeking HRB funding must consult the HRB call webpage and FAQs for important eligibility information: <a href="https://www.hrb.ie/funding/funding-schemes/all-funding-schemes/">https://www.hrb.ie/funding/funding-schemes/all-funding-schemes/</a> Lead applicants (Principal Investigators) must be from a recognised HRB Host Institution ( <u>Policy on Approval of HRB Host Institutions</u> ) and meet specific criteria. Early Career Researcher Lead Applicants must have: <ul style="list-style-type: none"> <li>• A PhD or have been granted PhD equivalence by the HRB before submission.</li> <li>• At least four years and up to seven years active post PhD (or equivalent) research experience.</li> </ul>
<b>Eligible costs</b>	Funding available: €430,000 (inclusive of overheads) for partners Coordinators may request up to €530,000. This is inclusive of overheads (in line with <u>HRB’s Policy on usage of overheads</u> ) and pension contributions and will cover research related costs including: <ul style="list-style-type: none"> <li>• Salary related costs</li> <li>• Direct running costs, including patient-related costs and costs to support interventional studies</li> <li>• Patient, Carers and Public and Involvement (PPI) costs</li> <li>• Small equipment costs (€10,000)</li> <li>• FAIR data management costs</li> <li>• Dissemination and knowledge exchange costs</li> </ul> For consortium coordinators, the additional €100,000 for coordination-specific activities will not cover equipment or consumables.
<b>Additional documents required</b>	<ul style="list-style-type: none"> <li>• Applicants must complete a <u>Lead Applicant eligibility form</u> at submission to provide details on the PI’s track record for eligibility checks.</li> <li>• A letter of support will be required at submission stage for any Lead Applicants who do not have a permanent post at a HRB Host Institution and for those in Adjunct positions. Please refer to the guidance on the <u>HRB scheme page</u> for further information.</li> <li>• Applicants must complete HRB’s Budget and Deliverables templates at full proposal stage. These will be supplied after invitation to submit a full proposal.</li> </ul>

<b>Eligible One Health settings</b>	At least one of the settings must be in Human Health and the Irish partner's activities must primarily target this area.
<b>Eligible experimental approaches</b>	Irish Partner(s) are not eligible for HRB funding for: <ul style="list-style-type: none"> <li>Proposals involving basic biomedical research.</li> <li>Research intended to create human embryos solely for the purposes of research or for the purposes of stem cell procurement, including by means of somatic cell nuclear transfer.</li> </ul>
<b>Further information</b>	All Irish partners who are undertaking feasibility and/or interventional studies must adhere to the <u><a href="#">HRB Clinical Trial and Interventions Research Governance Policy</a></u> .  HRB grant holders are required to submit grant reports as outlined in their grant contracts and the most recent <u><a href="#">HRB General Terms and Conditions for Research Awards</a></u> . These include Annual and Final reports.  Please refer to HRB's guidance on the <u><a href="#">HRB scheme page</a></u> or contact Siobhán Hackett at <a href="mailto:eujointprogrammes@hrb.ie">eujointprogrammes@hrb.ie</a> for full information.

<b>Israel – CSO-MOH Chief Scientist Office, Ministry of Health</b>	
<b>Specific National/ Regional rules</b>	CSO-MOH (Israel) will only fund proposals with relation to Human Health. PI should hold a Ph.D., M.D., D.M.D., D. Sc or equivalent degree and employed by an eligible institution ( hospitals, clinics, laboratories, academic and public research institutions Research will not be funded simultaneously by CSO-MOH on more than one grant (Era-NET or national). Researchers can not apply for more than one grant from any ERA-NET funded by CSO-MOH or submit more than one proposal for any programme.
<b>Eligible costs</b>	Materials and consumables; Travel (up to 10%); No salaries for PIs; No heavy equipment, Institutional overhead 10%.  Available budget: 0.32M (up to 2 projects. 140K per project + additional 20K per project coordinators)
<b>Additional documents required</b>	Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including budget distribution. No submission of abstract can result in declaration of the consortium as ineligible. If the application involves human or animal experiments, bioethics approvals must be submitted with the application or up to 4 months later.
<b>Eligible One Health settings</b>	Human health, Animal health, Environmental health (Only in relation to human health).
<b>Eligible experimental approaches</b>	Standard National Grant Conditions apply
<b>Further information</b>	Please see detailed instructions of application at the national level and reporting at <a href="https://www.gov.il/he/service/era-net-instructions-for-israeli-researchers">https://www.gov.il/he/service/era-net-instructions-for-israeli-researchers</a>

<p><b>Italy – FRRB</b>  <b>Fondazione Regionale per la Ricerca Biomedica</b></p>	
<p><b>Specific National/ Regional rules</b></p>	<p><b>MAXIMUM TWO PARTNERS from Lombardy PER PROJECT</b>  Eligible applicants:</p> <ol style="list-style-type: none"> <li>1. Public or Private Italian IRCCS (Scientific Institutes for Health Research, Hospitalization and Health Care)</li> <li>2. Public Health Care Providers (ASST)</li> <li>3. Agenzie di Tutela della Salute (ATS)</li> <li>4. Azienda Regionale Emergenza Urgenza (AREU)</li> <li>5. Universities - only in in partnership with one of the organizations above (1,2,3,4) located in Lombardy and requesting funding to FRRB</li> <li>6. Research Institutes - only in in partnership with one of the organizations above (1,2,3,4) located in Lombardy and requesting funding to FRRB.</li> </ol> <p>Please refer to the definition of research institutes and organisations on the FRRB webpage <a href="https://www.frrb.it/it/jpiamr-jtc2024">https://www.frrb.it/it/jpiamr-jtc2024</a>.  All applicants must be located in Lombardy and their activities should take place in Lombardy.  Enterprises and for-profit Organisation are NOT eligible.</p>
<p><b>Eligible costs</b></p>	<p>Direct costs:</p> <ul style="list-style-type: none"> <li>• Personnel (for public IRCCS and ASST, ATS and AREU, ONLY staff recruited specifically on the project). Personnel costs of PIs who have a permanent contract (contratto indeterminato) with their own organisation are NOT eligible.</li> <li>• Consumables, animals purchase, maintenance and breeding.</li> <li>• Equipment (on hire or eligible amortization rate).</li> <li>• Travel: max 10% of the total direct costs (overheads and subcontracting costs excluded).</li> <li>• Publications (only Open Access): max 5% of the total direct costs (overheads and subcontracting costs excluded).</li> <li>• Overheads: 20% flat rate calculated on direct costs (Subcontracting costs excluded from this calculation).</li> <li>• Other direct costs: please include here other costs, including those related to patient involvement (insurance, reimbursement, etc.).</li> <li>• Subcontracting: max 20% of the total direct costs (overheads costs excluded).</li> </ul> <p>FRRB will require the submission of a financial audit certificate together with the final financial report. This cost, to be included under the “Subcontracting” category will be eligible up to a maximum of € 8.000. Only costs generated over the lifetime of the project will be considered eligible.</p> <p><b>Rules regarding the Principal Investigator (PI):</b></p> <ol style="list-style-type: none"> <li>1. A PI cannot simultaneously hold more than one FRRB grant. PIs who are currently FRRB grant holders cannot apply to a new JTC unless their project is closed before the deadline of the new JTC pre-proposals. A project is considered closed when the final financial and scientific reports have been sent to FRRB. This rule applies only to PIs, not to team members.</li> <li>2. Personnel costs of PIs who have a permanent contract with their own organisation are <b>NOT</b> eligible.</li> </ol>
<p><b>Additional documents required</b></p>	<p>It is not necessary to send the proposal to FRRB. However, FRRB requires a <b>Pre-eligibility form</b>. According to internal procedures, FRRB will carry out an <b>eligibility check</b> to potential applicants prior to the submission of the pre-proposals.  The eligibility check will be based on the verification of a dedicated form (“<b>Pre-eligibility form</b>”), also available on the FRRB institutional website, to be returned, by email, to FRRB (<a href="mailto:progetti@frrb.it">progetti@frrb.it</a>), duly completed and signed by</p>

	<p>the Principal Investigator <u>at least 10 working days</u> before the pre-proposal submission deadline.</p> <p>FRRB will provide feedback on the “<i>Pre-eligibility form</i>”, <b>ONLY</b> in case of major non-eligibility issues.</p> <p>Principal Investigators (PIs) who submit a proposal without sending the “<i>Pre-eligibility form</i>” to FRRB beforehand will be automatically excluded.</p> <p>In addition, FRRB provides an excel sheet to help applicants abide by FRRB funding rules. This form is meant to support the PIs in the elaboration of the proposal budget, but it does not need to be sent to FRRB.</p> <p>Information and instructions on how to fill the “<i>Pre-eligibility form</i>” will be published on the dedicated webpage <a href="https://www.frrb.it/it/jpiamr-jtc2024">https://www.frrb.it/it/jpiamr-jtc2024</a></p> <p>Following the award, Lombardy beneficiaries will be requested to submit annual scientific and financial reports.</p>
<b>Eligible One Health settings</b>	Only Human Health area will be eligible for funding.
<b>Eligible experimental approaches</b>	Biomedical research ONLY in human settings. In case of clinical studies, the size and the duration should be compatible with the project timeline- studies should be completed by the end of the project.
<b>Further information</b>	Maximum € 500,000 <b>per project</b> (in case of two Lombardy partners in the same consortium, the amount of € 500,000 will be shared).

<b>Italy – It-MoH Italian Ministry of Health</b>	
<b>Specific National/ Regional rules</b>	<p>Only IRCCS (Istituti di Ricovero e Cura a Carattere Scientifico) researchers are eligible to apply.</p> <p>Organisations not eligible to apply: Universities, other research Institutes, companies.</p> <p>Maximum funding per grant awarded to a project partner: 400.000 € per project</p> <p>Simultaneous PI participation in different 2024 JTCs funded by the Ministry of Health is not allowed.</p> <p>No more than two Italian PIs (Principal Investigators) are eligible to apply for the same project.</p> <p>If 2 PIs applying for funding from IT MoH participate in the same consortium, the maximum total budget of 400.000€ will be splitted among the two.</p>
<b>Eligible costs</b>	<p>Available budget: 0.800M</p> <p>Direct Costs:</p> <ul style="list-style-type: none"> <li>• Personnel (only temporary contracts, max 50%);</li> <li>• Consumables;</li> <li>• Animals;</li> <li>• Equipment (only on hire);</li> <li>• Travel (max 10%);</li> <li>• Documentation (Max 1%)</li> </ul> <p>Indirect Costs:</p> <ul style="list-style-type: none"> <li>• Overhead (max 10%, included in the total);</li> </ul> <p>Other indirect costs are not eligible.</p> <p>Transfer of eligible funds abroad is not allowed.</p> <p>Subcontracts are allowed only upon approval, by presenting via Workflow – code ER, a request together with the National pre-eligibility form, the latest 20 days before the deadline of the pre-proposal submission (the form can be requested to national contact persons)</p>

<b>Additional documents required</b>	<p>In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicant prior to the submission of the proposals. To this end, it is mandatory that the applicants fill out and return to the IT-MoH a pre-submission eligibility check form through their IRCCS, using WFR System-&gt; ER communication code, before submitting their proposal to the Joint Call Secretariat.</p> <p>It is strongly recommended that the form, completed and duly signed, is returned at least 10 working days before the proposal submission deadline. Applicants will be sent written notification of their eligibility status. Changes in acronyms and budgets provided in the pre-submission eligibility check are not allowed.</p> <p>Submission of annual scientific and financial reports at the national level will be required according to the rules of the Ministry of Health (Ricerca Corrente).</p> <p>Further information on the rules of the Ministry of Health can be requested to the national contact persons.</p>
<b>Eligible One Health settings</b>	Human health,
<b>Eligible experimental approaches</b>	<p>According to the rules of the Ministry of Health (Ricerca Corrente).</p> <p>Further information on the rules of the Ministry of Health can be requested to the national contact persons.</p>
<b>Further information</b>	<p>Italian PAOs can be funded as a sub-contracts of an IRCCS if they fulfil the eligibility criteria of the EC. The maximum cost eligible for a sub-contract is 25.000 Euros (from the IRCCS Budget).</p> <p>Italian PAOs can still participate in Consortia as “Collaborators” with their own funds</p> <p>The pre-eligibility form can be downloaded here:  <a href="https://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf">https://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf</a></p>

<b>Latvia– LCS Latvia Council of Science</b>	
<b>Specific National/ Regional rules</b>	<p>Only the following legal persons are eligible:</p> <p>1) Research institutions registered in the Latvian Registry of Scientific Institutions, e.g.  - Research Institutes  - Universities  and must have the status of Research and knowledge dissemination organization (Regulation EC 651/2014)</p> <p>2) Business enterprises entered into the Latvian Commercial registry as companies, assumed they are eligible to do the specific research and have specific capacity and resources to do the research in Latvia and have their main activity in Latvia. Limitations of EU legislation apply (R651/2014) together with financial reporting requirements, in case this is state aid. Two previous statements with sworn auditor’s approval should be provided and they must reflect the correspondence to the regulation as well as evidence of previous scientific activity and presence of capacity.</p>
<b>Eligible costs</b>	<ol style="list-style-type: none"> <li>1. Personnel costs incl. taxes;</li> <li>2. Consumables;</li> </ol>

	<ol style="list-style-type: none"> <li>3. Subcontracts (up to 25% of direct costs), needs detailed justification, includes all external services, project core activities cannot be subcontracted;</li> <li>4. Equipment (only depreciation costs during project directly attributable to project tasks);</li> <li>5. Replaceable and fully consumable during project elements of equipment (e.g. electrodes);</li> <li>6. Travels (according to travel plan);</li> <li>7. Indirect costs (up to 25% of direct costs excluding subcontracting).</li> </ol>
<b>Additional documents required</b>	<p>Not at the application phase.</p> <p>To receive funding by LCS, Consortium agreement duly signed should be presented.</p> <p>Enterprises shall provide audited statements of 2 previous closed financial periods on request.</p> <p>Final audit according to the LCS regulations, by a sworn auditor.</p> <p>Annual financial and scientific reporting is mandatory.</p>
<b>Eligible One Health settings</b>	Human, animal, environment
<b>Eligible experimental approaches</b>	Preclinical cell animal, clinical only proof of concept
<b>Further information</b>	<p>Support is provided according to Provisions Nr 259, 26.05.2015 of the Latvian Cabinet of Ministers (<a href="http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibaistarptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma">http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibaistarptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma</a>)</p> <p>These provisions should be respected without exceptions. The maximum rates should respect the Provisions. The requirements in the provisions to specific applicant groups must be respected.</p> <p>LCS cannot fund implementation support, nor training activities.</p> <p>LCS is funding only research.</p> <p>Max 2 Latvian participants per proposal.</p>

<b>Lithuania – LMT Research Council of Lithuania</b>	
<b>Specific National/ Regional rules</b>	<p><b>Eligibility:</b></p> <p>Eligible for funding institutions are Lithuanian research and higher education institutions that are included in the Register of Education and Research institutions, public healthcare institutions, academy of science mentioned in the state Law on Science and Studies, other state public institutions such as National libraries, archives, museums. Beneficiary institution (grant holder) manage the state budget funds allocated to the project following the rules stated in the legal acts, as well as representing the project partners (if applicable 'project partner' means public or private legal entity that, together with the eligible institution, created the conditions for project implementation).</p> <p><b>Maximum funding per grant awarded to a project partner:</b></p> <p>Within a single project proposal, the maximum funding can be up to EUR 150 000 – for one consortium partner; up to EUR 200 000 – for a coordinator or 2 eligible LT partners in a consortium; up to EUR 250 000 – for a coordinator and 1 eligible LT partner in a consortium</p>

<b>Eligible costs</b>	Only costs (direct) generated during the lifetime of the project, related to project are eligible. Direct costs: personnel, travel, purchase (assets, services, consumables), subcontracting. Overheads (indirect costs): up to 20 % from direct costs.
<b>Additional documents required</b>	no
<b>Eligible One Health settings</b>	All
<b>Eligible experimental approaches</b>	All relevant to the call
<b>Further information</b>	Please contact National contact person and consult national call text and the <a href="#">webpage</a>

<b>Moldova – ANCD Agentia Nationala Pentru Cercetare Si Dezvoltare</b>	
<b>Specific National/ Regional rules</b>	Government Decision 382/2019 regarding the Methodology for financing projects in the fields of research and innovation <a href="https://www.legis.md/cautare/getResults?doc_id=128339&amp;lang=ro">https://www.legis.md/cautare/getResults?doc_id=128339&amp;lang=ro</a>
<b>Eligible costs</b>	a) the remuneration of the staff who are part of the research team, in compliance with the limits provided by the legislation in the budgetary sector and the related normative framework - up to 80%, including the taxes paid by the employer; <i>note</i> : scientific researchers indicated for remuneration from the state budget, will take into account not to exceed the 1.5 work rate in the projects financed by the Agency. b) procurement of raw materials, consumables, including reagents, animals, laboratory inventory necessary to carry out experiments for the purpose of realizing the project - up to 50%; c) the organization of scientific events (conferences, seminars, symposia, workshops, etc.) during the duration of the project - up to 10%; d) business trips abroad and in the country according to normative acts - up to 20%; e) editing and publishing monographs, scientific articles, scientific magazines, including the publication fee - up to 10%; f) services related to the project (experimental and production works) - up to 50%.
<b>Additional documents required</b>	YES
<b>Eligible One Health settings</b>	Eligible
<b>Eligible experimental approaches</b>	Eligible
<b>Further information</b>	NO

<b>Netherlands – ZonMw Zorgonderzoek Nederland Zon</b>	
<b>Specific National/ Regional rules</b>	Only research organisations according to EC Framework for State aid for research and development and innovation (2014/C 198/01) are eligible for funding. See: <a href="https://eur-lex.europa.eu/legal-content/NL/TXT/?uri=CELEX%3A52014XC0627%2801%29">https://eur-lex.europa.eu/legal-content/NL/TXT/?uri=CELEX%3A52014XC0627%2801%29</a>

	<p><b>Note:</b> A limited part of the requested national budget can be used for outsourcing. Otherwise, parties other than mentioned above can only participate as a non-funded partner, and need to secure their own funding in order to be involved in a project.</p> <p>ZonMw will avoid double funding and will not finance projects or part of projects that have been funded through other calls. ZonMw will cross-check the proposals submitted to ZonMw through the national and international calls for possible demands of double funding.</p>
<b>Eligible costs</b>	<p>Relevant project expenses, such as:</p> <ul style="list-style-type: none"> <li>– Salary-related costs according to <u>most recent NFU or VSNU table</u></li> <li>– Travel costs</li> <li>– Direct running costs</li> <li>– Dissemination and knowledge exchange costs</li> <li>– Data management / data steward</li> <li>– Open access costs with a maximum of € 5000,- per project</li> </ul> <p>ZonMw does not cover overhead costs. There will be a maximum of € 250.000 per consortium available (1 Dutch participant in the consortium: max. € 250.000, 2 Dutch participants in the consortium: max. € 250.000 for the both of them together).</p> <p>The ZonMw Grant Terms and Conditions are applicable. See: <a href="https://www.zonmw.nl/en/news-and-funding/funding/grant-conditions-and-finances/">https://www.zonmw.nl/en/news-and-funding/funding/grant-conditions-and-finances/</a></p>
<b>Additional documents required</b>	<p>Awarded projects will need to deliver a Consortium Agreement and Data Management Plan. With regards to the Consortium Agreement ZonMw requests an unsigned copy of the CA before the start of the project and a copy of the CA, signed by all partners, within 12 months after the project start date.</p>
<b>Eligible One Health settings</b>	<p>All one health settings are eligible.</p>
<b>Eligible experimental approaches</b>	<p>No particular conditions.</p>
<b>Further information</b>	<ul style="list-style-type: none"> <li>– ZonMw will also fund Social Sciences.</li> <li>– In case the joint proposal is recommended for funding, Dutch applicants will have to submit a formal application through MijnZonMw.</li> <li>– Awards will be subject to standard ZonMw Grant Terms and Conditions.</li> <li>– All publications resulting from scientific research wholly or partly funded by ZonMw must immediately be made available in Open Access (without embargo), in accordance with the ZonMw Open Access policy. ZonMw accepts various Open Access routes. In addition to articles, ZonMw encourages recipients to make other types of scientific publications available in Open Access.</li> </ul> <p>Make sure to consult the ZonMw <a href="#">Open Access publication</a> and <a href="#">Data management</a> policies.</p>

<b>Norway – RCN</b> <b>The research Council of Norway</b>	
<b>Specific National/ Regional rules</b>	See national guidelines for Researcher projects
<b>Eligible costs</b>	0.6 M EUR for the total 3-year period. 200,000-300,000 EUR per project for the total 3-year periode. More if the partner is the project coordinator, then maximum 400 000 EUR for a three year project.



	PhD fellowships are not eligible within the RCN funding.
<b>Additional documents required</b>	No
<b>Eligible One Health settings</b>	Human health, animal health, environmental health
<b>Eligible experimental approaches</b>	Standard RCN Grant Conditions apply.
<b>Further information</b>	Private industry is not eligible.

<b>Poland – NCN National Science Centre</b>	
<b>Specific National/ Regional rules</b>	<p>National participation rules are given in the <u>UNISONO Resolution No. 32/2023 of the Council of National Science Centre, dated March 16, 2023</u>. The translation into English will be published in the call announcement. Please note:</p> <ul style="list-style-type: none"> <li>• project tasks to be carried out by Polish research teams may involve only basic research i.e. experimental or theoretical endeavours undertaken to gain new knowledge of the foundations of phenomena and observable facts, without any direct commercial use;</li> <li>• if two or more different Polish institutions apply as partners within one international project consortium and seek funding from the NCN, they must apply to the NCN as a group of entities</li> <li>• proposals may involve non-commercial clinical trials related to a medicinal product or a medical device;</li> <li>• NCN funds projects that last either 24 or 36 months;</li> <li>• institutions for which funding would constitute state aid cannot participate in this call;</li> <li>• proposals involving any cooperation between Polish and Russian institutions are not eligible (including cooperation with non-funded partners from the Russian Federation).</li> </ul>
<b>Eligible costs</b>	<p>All costs relevant, necessary and directly connected to the proposed research project including:</p> <ol style="list-style-type: none"> <li>1. Personnel costs – permanent and/or temporary; including post-doc(s). <b>Limits apply</b> depending on the size of the research team – please refer to the <u>UNISONO resolution</u>.</li> <li>2. Salaries and scholarships for students and PhD students;</li> <li>3. Equipment: up to 500,000 PLN per unit;</li> <li>4. Other direct costs: materials, devices and software, outsourcing and subcontracting, travel and subsistence costs, visits and consultations, collective investigators;</li> <li>5. Overheads/indirect costs: there are two types of indirect costs, both calculated as lump sums: <ul style="list-style-type: none"> <li>– indirect costs of Open Access (publications and data) - up to 2% of total direct costs of the project</li> <li>– other indirect costs - up to 20% of total direct costs of the project.</li> </ul> </li> </ol> <p>Other indirect costs include administrative personnel costs as well as costs of organizing conferences, workshops, seminars or meetings. The amount budgeted for indirect costs may not be increased during the course of a research project.</p> <p>The total funding the NCN allocated for <b>all</b> Polish research teams in the call is <b>500 000 EUR</b> (2 266 450 PLN).</p>
<b>Additional documents required</b>	At the pre-proposal stage applicants must consult the Polish team’s budget table with NCN project officers <b>no later than February 23, 2024</b> . At the full

	proposal stage, applicants must submit their national proposals in the Polish submission system (OSF). National proposals must state the budgets in Polish currency using the conversion rate of <b>1 EUR = 4,5329 PLN</b> .
<b>Eligible One Health settings</b>	As described in the call text.

<b>Spain – ISCIII National Institute of Health Carlos III</b>	
<b>Specific National/ Regional rules</b>	<p><b>National Programme:</b> Acción Estratégica en Salud 2024 (AES 2024)  <b>Initial funding pre-commitment:</b> 1.000.000 € (pending of approval of Spanish State Budget)  <b>Number of proposals</b> that could be funded: 3-4  <b>Projects’ duration:</b> from 24 months to 36 months</p> <p><b>Maximum funding per awarded Spanish project:</b>  If a Spanish Partner requesting funding to the ISCIII <b>IS NOT</b> the Coordinator of the transnational project:</p> <ul style="list-style-type: none"> <li>• <b>220.000€</b> (overheads included), if there is only one Spanish Partner requesting funding to the ISCIII in the proposal.</li> <li>• <b>275.000€</b> (overheads included), if there are two Spanish Partners requesting funding to the ISCIII in the proposal.</li> </ul> <p>If a Spanish Partner requesting funding to the ISCIII <b>IS</b> the Coordinator of the transnational project:</p> <ul style="list-style-type: none"> <li>• <b>300.000€</b> (overheads included), if there is only one Spanish Partner in the proposal, acting as a coordinator.</li> <li>• <b>400.000€</b> (overheads included), if there is one Spanish Partner in addition to the Spanish Coordinator in the proposal, both requesting funding to the ISCIII.</li> </ul> <p><b>Eligible institutions:</b></p> <ul style="list-style-type: none"> <li>• <b>Accredited Health Research Institutes</b> (Institutos de Investigación Sanitaria acreditados, IIS). Accredited according to the RD 339/2004, of February 27th or RD 279/2016 (These institutions may manage research via a foundation regulated according to the Spanish Act 50/ 2002, of December 26th). See the list of IIS in this <a href="#">link</a>.</li> <li>• <b>Hospitals, primary health care or public health administration of the Spanish National Health System (SNS)</b>. These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation’s statutes may be submitted).</li> <li>• <b>CIBER</b>. Team members applying to the call must be from at least two groups belonging to CIBER in two different home institutions and one of these two should be a Hospital, primary health care or public health administration of the SNS or IIS). Please contact Cristina Rodríguez (<a href="mailto:cristina.rodriguez@ciberisciii.es">cristina.rodriguez@ciberisciii.es</a>) for more information related to CIBER’s eligibility.</li> <li>• <b>Public Research Institutions (OPIs)</b> as defined in article 47 of Law 14/2011, of 1 June, in accordance with the provisions of Royal Decree 202/2021, of 30 March, <b>Private health entities and institutions, public Universities and private Universities with proven R&amp;D activity capacity, other public R&amp;D centres</b>. These entities can only participate if they apply together with hospitals, primary health care or public health administration of the Spanish National Health System (or Accredited Health Research Institutes (IIS) in the same proposal. It is not</li> </ul>

	<p>allowed for these entities to apply independently, thus <b>there must be two beneficiary Spanish institutions requesting funding to ISCIII in the same proposal.</b></p> <ul style="list-style-type: none"> <li>• Applicants from <b>ISCIII</b> are eligible in the same conditions as Public Research Institution (OPI) above-mentioned. Eligibility criteria from <b>AESI 2024</b> apply</li> </ul> <p><b>NOT eligible institutions:</b></p> <ul style="list-style-type: none"> <li>• Those declared by AES 2024 as ineligible to receive funds by ISCIII <ul style="list-style-type: none"> <li>• Particularly for this call, it will not be eligible the National Technological Centres and National Centres for supporting technological innovation that are inscribed in the Register according by RD 2093/2008, of 19 December.</li> </ul> </li> </ul>
<p><b>Eligibility of Principal Investigator (PI) and team members</b></p>	<ul style="list-style-type: none"> <li>• Principal Investigators (PI) shall mandatory have <b>PhD degree.</b></li> <li>• Principal Investigators (PI) can only participate in one project proposal per call.</li> <li>• Principal Investigators (PIs) belonging to an <b>Accredited Health Research Institutes (IIS)</b> could apply <b>only from the IIS.</b></li> <li>• The Principal Investigator (PI) and all members of the research group must belong to the eligible institutions in the call.</li> <li>• Only one PI per beneficiary institution may be funded within the same proposal.</li> <li>• PIs that has an ongoing International Collaboration (PCIN) project of the same initiative and purpose that this call and that the project has an ending date after the <b>31st December 2024</b> will not be able to apply for this call. This incompatibility will affect only to the PI. And this incompatibility will not apply in the case that the PI participate as coordinator in the new application or in the ongoing project.</li> <li>• For additional incompatibilities please review AES 2024.</li> </ul> <p><b>Excluded personnel as PI:</b></p> <ul style="list-style-type: none"> <li>• Those undergoing a postgraduate training in Health Specialization (MIR, EIR, FIR, QIR, BIR, PIR, RFIR).</li> <li>• Those undergoing research training (e.g. PhD students, or “Río Hortega” contracts).</li> <li>• Those undergoing postdoctoral training (e.g. “Sara Borrell” or “Juan de la Cierva” contracts).</li> <li>• Researchers contracted by a RICOR and platforms funded by ISCIII</li> </ul>
<p><b>Eligible costs</b></p>	<p><b>Personnel costs:</b></p> <ul style="list-style-type: none"> <li>• Personnel costs will be eligible for contracts with the needed professional category (superior technician, BSc (grado), MSc (máster), PhD (doctor) for the project development accordingly to the published salary tables in ISCIII’s webpage/AES2024. Personnel cost will precisely adhere to the salary tables, no other amount will be considered, either upper nor lower.</li> <li>• Contracts for PhD students will be done in the framework of National Subprogramme for Training (scholarships are not eligible).</li> <li>• Personnel costs will NOT be eligible when they correspond to civil servants or the equivalent personnel (as specified in the Art. 3.4 of AES2024) either employed by the beneficiary entities or belonging to the research team.</li> <li>• Personnel costs will be eligible when corresponding to contracts under the frame of Art. 23bis of Law 14/2011, 1st June, following the specifications established in AES2024.</li> </ul>

	<p><b>Other eligible costs:</b> Current costs, small scientific equipment, disposable materials, travelling expenses, complementary expenses (use of central and general research support services of the beneficiary entity), publication and dissemination of results and other costs as included in <b>AES 2024</b> that can be justified as necessary to carry out the proposed activities.</p> <ul style="list-style-type: none"> <li>• <b>Overheads</b>, according to AES 2024 (25%)</li> <li>• Double funding of the same concept is not allowed</li> <li>• National applications will be required by ISCII from IPs whose proposal are approved for funding.</li> </ul>
<b>Additional documents required</b>	<p><b>Submission of a pre-eligibility form needed at national level</b></p> <p>In order to expedite the eligibility check process, it is mandatory that all the applicants submit the <u>CVA-ISCIII</u> of the PI. This document shall be submitted by the PI by electronic email before the proposal submission deadline to: <a href="mailto:cbarco@isciii.es">cbarco@isciii.es</a></p> <p><b>Submission of the proposal at the national level</b></p> <ul style="list-style-type: none"> <li>• Due to administrative and legal regulations, the Institute of Health Carlos III establishes the <b>31<sup>st</sup> October 2024</b> as the national deadline for the decision on fundable project consortia which includes Spanish partners to be funded by ISCIII. The National application period will be stated in AES 2024. Any concerned applicant in a proposal for which no final decision has been made by the deadline could be declared not fundable by ISCIII or delayed their funding to the following year</li> </ul>
<b>Eligible One Health settings</b>	Human health. Animal health can only be funded by ISCIII if the proposal is related with zoonotic diseases. Environment can only be funded if it has direct connection with human health
<b>Eligible experimental approaches</b>	Spanish groups that are involved on the performance of a clinical trial in the proposal, are recommended to include in their team a member from their scientific node of the EU Clinical Trials Network (SCReN or ECRIN-ERIC) or if it does not exist, a member from the personnel of their Clinical Research Supporting Platform of their institutions (UIC).
<b>Further information</b>	<p><b>Additional requirements on data and repositories</b></p> <ul style="list-style-type: none"> <li>• Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, data instruments survey tools. Regarding genomic data it is understood: association of complete genomes (GWAS), matrixes of de polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the "<u>ELIXIR Core Data Resources</u>", or if non-European repositories or data bases are to be used they must be certified by ELIXIR or the US National Center for Biotechnology Information (NCBI).</li> <li>• ISCIII may not fund any project that may require a repository and/or a data base without a plan ensuring sustainability and decommissioning after the end of funding.</li> </ul> <p><b>Use of Research infrastructures and platforms</b></p> <p>Researchers funded by ISCIII are encouraged to make use of the resources available through the European Research Infrastructures and the Spanish Platforms funded by ISCIII for supporting the biomedical and health R&amp;I.</p> <p><b>Acknowledgements</b></p>

	Any publication, data base, product or event protected with IPR or not, resulting from the granted project must acknowledge “Award no. XX by Instituto de Salud Carlos III (ISCIII) thorough AES 2024 and within the JPND framework” even after the end of the project, including other specific acknowledgments that could be requested by ISCIII to the granted project. For more information please see ISCIII’s ROR <a href="#">here</a> .
--	--

<b>Sweden – SRC Swedish Research Council</b>	
<b>Specific National/ Regional rules</b>	<ul style="list-style-type: none"> <li>• The applicant must be an individual researcher holding a PhD. Only researchers at an administrating organisation approved by the Swedish Research Council may apply. Please refer to general applicant eligibility requirements found <a href="#">here</a>.</li> <li>• The applicant may not have an ongoing JPIAMR project grant, OR any other project grant concerning the same project concept, funded by the Council, at the start of the grant period.</li> <li>• All Swedish applicants are encouraged to communicate with the JPIAMR national contact person regarding their intention to participate in the call, before submission of the consortium application.</li> <li>• Grant amount: Max. 3 500 000 SEK (approx. 303 000 Euro) per consortium with max 2 Swedish partners. Min. 1 200 000 SEK (approx. 105 000 Euro) per partner. Max 5 000 000 SEK (approx. 433 000 Euro) if a Swedish participant is the coordinator of the consortium. No funding of industrial partners. Use the exchange rate of 1 Euro = 11.55 SEK to calculate actual grant amounts for the application.</li> <li>• You can only take part in one consortium within this call, either as coordinator or partner.</li> <li>• All Swedish project leaders participating in the call for support from the Swedish Research Council shall also submit a parallel application using the Swedish Research Council’s application system Prisma. The application form in Prisma can be reached from the national call text at the SRC website (see links below).</li> </ul> <p><b>Parallel application is a mandatory eligibility criterion. Failure to submit the parallel application to the Swedish Research Council before the deadline of the Prisma call may result in the Swedish partner being declared ineligible.</b></p>
<b>Eligible costs</b>	<p>The project grant may be used to fund all types of project-related costs, such as salaries (including your own salary, however no more than corresponding to the person’s activity level in the project), running costs (such as consumables, travel including stays at research facilities, publication costs and minor equipment), premises and depreciation costs.</p> <p>Grants may not be used for scholarships. If a doctoral student participates, project funds may not be paid out as salary during teaching or other departmental duties.</p>
<b>Additional documents required</b>	A parallel application must be submitted in the SRC’s application system Prisma. See above.
<b>Eligible One Health settings</b>	All one health settings are eligible.
<b>Eligible experimental approaches</b>	No particular conditions
<b>Further information</b>	See national call texts in <a href="#">Swedish</a> and <a href="#">English</a> for all national requirements.

Switzerland – SNSF Swiss National Research Foundation	
<p><b>Specific National/ Regional rules</b></p>	<p>Applicants must comply with the <a href="#">SNSF Funding Regulations</a>, the <a href="#">General Implementation Regulations</a> , and the <a href="#">SNSF Regulations on Project Funding</a> . In particular, all Swiss based applicants and co-applicants seeking SNSF support must be eligible for SNSF Project Funding. Please note that applications submitted by a non-eligible person will not be considered nor evaluated. Please refer to the regulations and contact the national contact person for questions and re-assurance.</p> <p><b>Participation of Swiss-based partners requesting financial support from the SNSF is restricted to one project</b> (Art.6.3, <a href="#">SNSF Regulations on project funding</a>). They may, however, participate in other consortia projects as self-financed partners. Swiss-based partners requesting financial support from the SNSF may submit at most one proposal within this call.</p> <p>The maximum number of grants in the project funding scheme for the same funding period from the SNSF is limited to three grants, provided that at least one grant is for an EU consortium project or has been granted on the basis of a lead agency, Weave or International Co-investigator scheme evaluation. <b>Swiss-based investigators who already hold three SNSF grants in project funding cannot request financial support from the SNSF to participate in this call</b> (Article 13 of <a href="#">SNSF Regulations on Project Funding</a> ).</p> <p><b>Proposals with overlapping funding periods with ongoing SNSF projects</b> are only approved if the research projects pursue different goals (Article 17 of the <a href="#">SNSF Funding Regulations</a>).</p> <p><b>The SNSF exclusively funds research conducted for purposes that are not directly commercial.</b> Pursuant to the Research and Innovation Promotion Act RIPA and the legal framework of the SNSF, no research grants are awarded if the relevant research is conducted for directly commercial purposes or if the persons involved in the research work do not enjoy scientific independence.</p>
<p><b>Eligible costs</b></p>	<p><b>Eligible costs</b> are outlined in the <a href="#">SNSF Funding Regulations</a> (Art. 28) and the <a href="#">SNSF General Implementation Regulations</a> (Section 2).</p> <p><b>Project overhead costs cannot be applied for.</b> They are calculated on the basis of the research funding acquired by eligible institutions under eligible funding schemes. Overhead contributions are paid in retrospect at a flat rate to the institutions of the SNSF awardees.</p>
<p><b>Additional documents required</b></p>	<p><b>Mandatory, parallel submission of pre- and full-proposal via mySNF</b></p> <p>Swiss-based partners must submit pre-proposals and full proposals <b>via mySNF</b> at the same submission deadline than the consortium application. These submissions are mandatory and do not replace the submission of the consortium application to the Call Secretariat.</p> <p><b>Pre-proposal</b> forms are created by selecting "Projects: Partnership: JPI AMR: Pre-proposal".</p> <p><b>Full-proposal</b> forms are created by selecting "Projects: Partnership: JPI AMR: Full proposal" and are to be linked to the pre-proposal by selecting its number in the data container "Relation to pre-proposal".</p>

	<p><b>In case of multiple, Swiss-based partners participating in the same consortium</b>, only one application is to be submitted on <i>mySNF</i>, whereby one Swiss-based partner must act as "corresponding applicant" and the other Swiss-based partners are to be listed as "other applicants".</p> <p><b>International partners of the consortium</b> applying for funding at different funding agencies from the SNSF cannot be declared as "project partners" in the sense of article 11.2 of the SNSF Funding Regulations. For the submission via <i>mySNF</i>, they are to be declared as "consortium partners" instead and must apply for their funding at their respective research funding organisation.</p>
<b>Eligible One Health settings</b>	Yes (all settings including humans, plants, animals and the environment)
<b>Eligible experimental approaches</b>	Yes (no particular limitations)
<b>Further information</b>	<p>The SNSF provides a <b>minimum grant of 100'000 Swiss francs per project</b>. The SNSF provides a <b>maximum of 250,000 Swiss francs annually per applicant</b> of a project and a maximum of 1 million Swiss francs annually for the project as a whole (SNSF-funded part).</p> <p>Applicants should bear in mind that <b>the SNSF anticipates funding between 2 and 3 projects</b> under this call.</p> <p>Information available at:</p> <ul style="list-style-type: none"> <li>• <a href="#">SNSF Funding regulations</a></li> <li>• <a href="#">General Implementation Regulations</a></li> <li>• <a href="#">SNSF Regulations on Project Funding</a></li> </ul>

<b>United Kingdom – UKRI</b> <b>United Kingdom Research and Innovation</b>	
<b>Specific National/ Regional rules</b>	<p>Awards will be made through MRC on behalf of all UKRI Research Councils (AHRC, BBSRC, ESRC, EPSRC, MRC, NERC, STFC). Potential applicants are strongly advised to contact the National Call Secretariat, or the UK National Contact as detailed in Annex A of the Call, in advance of making an application, to resolve any eligibility queries.</p> <ul style="list-style-type: none"> <li>• Applicants must be eligible to receive UKRI research funding. Industrial partners may not request costs. Full details of eligibility for Research Council funding can be found on the UKRI website: <a href="https://www.ukri.org/apply-for-funding/how-to-apply/check-if-you-are-eligible-for-research-and-innovation-funding/">https://www.ukri.org/apply-for-funding/how-to-apply/check-if-you-are-eligible-for-research-and-innovation-funding/</a></li> <li>• Please see the UKRI Guidance for Applicants for full information of eligibility and resourcing of grants: <a href="https://www.ukri.org/apply-for-funding/how-to-apply/find-guidance-on-applying-for-funding/">https://www.ukri.org/apply-for-funding/how-to-apply/find-guidance-on-applying-for-funding/</a></li> <li>• For the purposes of this call, a 'partner' requesting funding from UKRI is a legal entity. Multiple researchers from the same legal entity form a single partner, but only one of these researchers should be named on the JPIAMR application form.</li> <li>• The UK component of applications should use full economic costings (fEC). The total amount requested must be the 80% fEC value. The submitting organisations must agree to find the balance of fEC for the project from other resources. In the 'financial plan' section of the JPIAMR application form, the 'sum requested' is the 80% fEC</li> </ul>

	<p>amount. The 'total' is the 100% fEC amount plus any further resources or in kind contributions.</p> <ul style="list-style-type: none"> <li>• Subject to conditions of eligibility and peer review being fully met, up to €2M will be available to UK researchers for this call. Individual consortia may request up to a maximum of €400 000 UK funding, per application. This maximum amount refers to the 80% fEC value and not the 100% fEC value.</li> <li>• Once the highest scoring projects have been funded, the remaining UKRI funds may be allocated to projects scoring lower than projects requesting more than the remaining funds available.</li> <li>• Applicants who intend to collaborate with industrial or other non-academic partners should note that any costs incurred, direct or otherwise, by these partners cannot be met by UKRI Research Councils and that these partners cannot claim funding.</li> <li>• Successful UK partners in transnational consortia will be required to upload a single application to UKRI within one month of the notice of award. This must replicate the UKRI component of the JPIAMR application and will not be peer-reviewed. A single UKRI award will be issued to all UK partners within a consortium. The UK partners must therefore identify which researcher is the lead UK applicant, who will be responsible for submitting the UKRI application and whose institution will be responsible for disbursing UKRI funds to any other UKRI-funded partners.</li> <li>• Awards are subject to UKRI <a href="#">Terms and Conditions</a> for funding. Award letters will include any additional terms and conditions specific to the call.</li> </ul>
<p><b>Eligible costs</b></p>	<p>Eligible costs include project-related costs incurred after the award start date, including:</p> <ul style="list-style-type: none"> <li>• Principal Investigators and Co-Investigators time</li> <li>• Research and technical staff</li> <li>• Estates and Indirect costs</li> <li>• Animal costs</li> <li>• Travel and Subsistence</li> <li>• Equipment</li> <li>• Consumables</li> <li>• Recruitment and advertising costs for staff directly employed on the project</li> <li>• Costs related to research data management</li> <li>• NHS Research costs.</li> </ul> <p>Ineligible costs include:</p> <ul style="list-style-type: none"> <li>• NHS support and NHS treatment costs</li> <li>• PhD students</li> <li>• Publication costs, including open access publication costs.</li> <li>• Industrial partners</li> </ul> <p>For more information regarding eligible costs, please see the <a href="#">MRC Guidance for Applicants</a>.</p>
<p><b>Additional documents required</b></p>	<ul style="list-style-type: none"> <li>• As well as the JPIAMR application form, applicants must also complete a UK Budget Proforma. <ul style="list-style-type: none"> <li>○ Costs should be included in pounds sterling (GBP) on the UK budget proforma (which can be downloaded from the call entry in the Funding Finder on UKRI's website) and included on the JPIAMR application form in Euros using an exchange rate of £1:€1.15.</li> <li>○ Applicants should include a statement on the UK budget proforma to confirm the exchange rate used, and that costs are</li> </ul> </li> </ul>



	<p>entered at 80% fEC according to standard Research Council funding policy.</p> <ul style="list-style-type: none"> <li>• Applications that incur excess treatment costs for studies involving patients will be required to complete a SoECAT form if invited for a full application. Please see the MRC Guidance for Applicants for further information.</li> </ul>
<b>Eligible One Health settings</b>	UKRI is able to support all research areas that fall within the remit of any of the UKRI Research Councils (AHRC, BBSRC, ESRC, EPSRC, MRC, NERC, and STFC). Potential applicants are strongly advised to contact the the UK National contact as detailed in Annex A of the Call, in advance of making an application, to resolve any eligibility queries.
<b>Eligible experimental approaches</b>	All experimental approaches, including in vitro, in silico and in vivo pre-clinical, phase I or II a clinical trials are eligible for funding.
<b>Further information</b>	For further details please refer to: <a href="https://www.ukri.org/apply-for-funding/how-to-apply/find-guidance-on-applying-for-funding/">https://www.ukri.org/apply-for-funding/how-to-apply/find-guidance-on-applying-for-funding/</a>